BioCardia, Inc. (BCDA) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 4.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $4.12M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $951.00K | (m) | (m) |
| 2025-12-31 | (m) | (m) | $2.50M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $5.29M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $980.00K | (m) | (m) |
| 2025-03-31 | (m) | (m) | $949.00K | (m) | (m) |
| 2024-12-31 | (m) | (m) | $2.37M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $4.93M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $1.42M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $949.00K | (m) | (m) |
| 2023-12-31 | (m) | (m) | $1.10M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $1.83M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $4.30M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $4.86M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $7.36M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $6.67M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $8.61M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $9.93M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $12.87M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $15.89M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $18.54M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $21.50M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $21.41M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $7.39M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $11.09M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $2.59M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $5.58M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $8.91M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $517.00K | (m) | (m) |
| 2019-03-31 | (m) | (m) | $2.84M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $5.36M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $4.82M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $6.83M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $9.65M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $12.69M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $13.33M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $15.11M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $19.03M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $21.35M | (m) | (m) |
| 2016-10-24 | (m) | (m) | $24.00M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $19.44M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $13.87M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $13.93M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $13.84M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $13.73M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $13.69M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $13.60M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $13.51M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $13.46M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $13.40M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $13.32M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $13.29M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $13.26M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $13.27M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $13.25M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $13.27M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $12.82M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $12.88M | (m) | (m) |
| 2012-03-31 | (m) | (m) | $12.65M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $12.68M | (m) | (m) |
| 2011-09-30 | (m) | (m) | $12.61M | (m) | (m) |
| 2011-06-30 | (m) | (m) | $12.69M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $241.00K | (m) | (m) |
| 2010-12-31 | (m) | (m) | $127.00K | (m) | (m) |
| 2010-09-30 | (m) | (m) | $196.00K | (m) | (m) |
| 2010-06-30 | (m) | (m) | $1.67M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $4.97M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |